Plain-English translation of NCT05394259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called PYLARIFY () PET-CT to see how well it can find cancer that has spread beyond the original tumor in patients with pancreatic cancer, liver cancer, or breast cancer. The researchers want to know if this new scan is more accurate than standard imaging tests at finding all the places where cancer may have spread. This information could help doctors make better treatment decisions.
Doctors need better tools to find all the places where cancer has spread, because missing even small areas of spread can affect treatment choices and outcomes. This trial is testing whether this new imaging medication can help doctors see cancer more clearly and completely than current standard scans.
If you join this trial, you will receive an injection of the new imaging medication through a vein, which takes about 5 seconds. You will then undergo a PET-CT imaging scan, which is similar to standard imaging but uses the new medication to help find areas where cancer may have spread. Depending on what the scan shows, your doctor may recommend a biopsy to confirm findings, which would be done as part of your regular cancer care. The study is small and focused on gathering information about how accurate and helpful this new scan is.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States